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Objective. To evaluate the accuracy and reliability of the medical decision based on the results of the hand scoring from a two-
channel recording device (ApneaLink) plus clinical data for the prescription of a CPAP assay in patients with suspected OSA.
Methods. 39 subjects were assessed in the sleep laboratory with polysomnography and ApneaLink. The patients completed the
Epworth sleepiness scale and a clinical history. Two blinded independent observers decided to prescribe CPAP according to
the results of the PSG (gold standard, observer A), ApneaLink (alternative method, observer B), and the clinical parameters.
Sensitivity and speciﬁcity of observer B on the indication of CPAP were calculated. The interobserver agreement for the indication
of CPAP was assessed using kappa statistics. Results. 38 subjects were included (26 men, mean age 47.5, mean RDI 28.7, mean
BMI 31.4kg/m2). The prevalence of OSA was 84%. The sensitivity and speciﬁcity of observer B to initiate a CPAP trial were 90.6%
and 100%, respectively. The interrater agreement for the prescription of CPAP was good (kappa: 0.75). Conclusion. This study has
shownthattheuseofApneaLinkplusclinicaldatahasmadeitpossibletoindicateCPAPreliablyinmostpatientswithhigh-clinical
pretest for OSA.
1.Introduction
Obstructive sleep apnea (OSA) is a major health problem
due to its prevalence rates of 2–4% in middle-aged people
[1] and signiﬁcant morbidity [2, 3] and mortality [4]
reported in patientswiththiscondition. Continuous positive
airway pressure (CPAP) is an eﬀective treatment commonly
prescribed for symptomatic patients with obstructive sleep
apnea. It is costeﬀective [5] and reduces daytime sleepiness
[6], rates of motor vehicle accidents [7], and blood pressure
[8]. The American Thoracic Society [9] and the American
Academy of Sleep Medicine [10] recommend supervised
polysomnography (PSG) in the sleep laboratory over two
nights for the diagnosis of obstructive sleep apnea and initi-
ation of CPAP. This approach to a highly prevalent condition
results in inevitable discrepancies between the demand for
services and the current capacity of sleep laboratories [11].
Because the treatment of sleep apnea provides many beneﬁts
to patients and society, it is imperative to develop strategies
that are less complex than the traditional approach based on
PSG to expedite the diagnosis and treatment of patients with
OSA.
The ApneaLink is a two-channel screening tool for sleep
apnea. The device consists of a nasal cannula attached to
a small case that houses a pressure transducer and a pulse
o x i m e t e r .I ti sh e l di np l a c eb yab e l tw o r na r o u n dt h e
user’s chest. It has good potential as a simple screening
device, particularly because it allows the manual review and
scoring of the raw data. There are several reports which have
evaluated the performance of the automatic analysis of nasal
pressure from the ApneaLink device against polysomnog-
raphy to diagnosis sleep apnea [12–15]. Furthermore, we
have recently demonstrated that the manual analysis of
data using an AHI (ApneaLink) and an RDI (PSG) ≥5a s2 Sleep Disorders
criteria for OSA has showed a sensitivity and speciﬁcity
nearly 90% [16]. Thus, the objective of this study was to
evaluate the accuracy and reliability of the medical decision
based on the results of the hand scoring from a two-channel
recording device (ApneaLink) plus clinical data (excessive
daytime sleepiness, cardiovascular comorbidities, and type
2 diabetes) for the prescription of CPAP in patients with
suspected OSA.
2. Methods
2.1. Patients. Forty consecutive patients referred to the
Hospital Alem´ an Sleep Laboratory for the investigation
of possible OSA were invited to participate in the study.
The inclusion criteria were patients of both sexes with
suspected OSA (snoring with/without other symptoms such
as apneas referred by someone and/or somnolence), age
equal to or over 18 years old, and informed consent. The
patients who used oxygen, CPAP or some modality of
noninvasive mechanical respiratory assistance during PSG
and those subjects suspected of having congestive heart
failure,neuromusculardisease,insomnia,parasomnias,peri-
odiclimbmovementdisorder,circadianrhythmdisorders,or
narcolepsy by medical history were excluded from the study.
The polysomnographies with artefacts in EEG or respiratory
channels (airﬂow, thoracoabdominal movements and SO2)
that did not allow the reading of the sleep stages or the
respiratory events or with less than 180 minutes of total
sleep time and the recordings of ApneaLink with less than
4h of manual evaluation period were not considered for
analysis.
2.2. Study Protocol. The subjects were assessed in the sleep
laboratory simultaneously with polysomnography (PSG)
and ApneaLink. Prior to the polysomnography, the patients
completed the Spanish version of the Epworth sleepiness
scale (ESS) [17] and a clinical history (see Table 1). Two
independent blinded observers reviewed the results from
the polysomnography (observer A, ED), the ApneaLink
(observer B, CN), and the clinical data. Then, we simulated
a situation in which both observers could initiate treatment
with CPAP in patients with a diagnosis of OSA based on the
results from the polysomnography (observer A), ApneaLink
(observer B), and clinical parameters. The reference method
to prescribe CPAP arose from symptoms and the respiratory
disturbance index (RDI) from PSG (observer A). On the
other hand, the alternative method to prescribe CPAP was
based upon the symptoms and the apnea/hypopnea index
of ApneaLink (observer B). Observer A decided to prescribe
CPAP in those patients who showed an RDI ≥15 regardless
of the patients’ symptoms or associated comorbidities or
when the RDI was between 5 and 15 in a patient with
excessive daytime sleepiness (Epworth >10) or any of the
following comorbidities: hypertension, cardiac arrhythmias,
coronary heart disease, cerebral vascular disease, or type 2
diabetes [18, 19]. On the other hand, observer B decided
to initiate a CPAP trial in those patients with any of
the following conditions: (1) ApneaLink compatible with
Table 1: Clinical parameters.
(1) Occupation
(2) Alcohol consumption
(3) Smoking
(4) Body mass index (BMI)
(5) Berlin questionnaire
(6) Epworth sleepiness scale
(5) Comorbidities
Chronic obstructive pulmonary disease
Asthma
Pulmonary ﬁbrosis
Pulmonary hypertension
Coronary arterial disease
Hypertension
Cardiac arrhythmia
Cardiac failure
Cerebrovascular disease
Diabetes mellitus
Hypothyroidism
Acromegaly
Menopause
Nasal obstruction, rhinitis
Neuromuscular diseases
Other diseases
(6) Medications
(7) Other sleep disorders
Sleep deprivation
Restless legs syndrome
Narcolepsy
Insomnia
Other sleep disorders
moderate to severe OSA (AHI ≥15) or (2) ApneaLink
consistent with mild to moderate OSA (AHI ≥5–<15) plus
the presence of excessive daytime sleepiness (Epworth >10)
or any comorbidities.
2.3. Measurements
2.3.1. Polysomnography. All the patients underwent
overnight polysomnography with a computerised
polysomnographic system (Mini PC, Akonic, Buenos
Aires, Argentina or Harmonie, Stellate Systems, Canada)
(F4/A1, C4/A1, and O2/A1), bilateral electrooculogram,
submental electromyogram, bilateral leg electromyogram,
and electrocardiogram. Airﬂow was measured by nasal
pressure and oral thermistor; respiratory eﬀort was assessed
by a thoracoabdominal piezoelectric belt, and oxygen
saturation (SO2) was recorded using a ﬁnger probe (Nonin,
Plymouth, Minn, USA). The polysomnographies were
registered from 10.30–11.30PM to 05-06AM. On the day of
the study, the patients were given the following instructions:
(1) to avoid napping and not to drink alcohol or beverages
with caﬀeine (coﬀee, tea, and cola drinks); (2) to continueSleep Disorders 3
the usual medication; (3) to eat supper between 8.30 and
9.30PM; (4) to report to the sleep lab between 10.30 and
11.30PM.
PSG Analysis. PSG reading was performed manually by two
widely experienced medical staﬀ members who were blind
to the operator that analysed the ApneaLink. The sleep
stages were analysed in 30s epochs according to interna-
tional criteria [20]. The arousals were identiﬁed following
the American Sleep Disorder Association recommendations
[21]. The analysis of apneas, hypopneas, and respiratory
eﬀort related arousals (RERAs) were in agreement with the
international criteria [22,23]. The followingdeﬁnitions were
used.
(i) Respiratory disturbance index (RDI): number of
apneas plus hypopneas plus RERAs per hour of sleep
[24].
(ii) OSA was deﬁned as an RDI ≥5.
(iii) Severity of OSA: mild = RDI ≥5–<15; moderate =
RDI ≥15–<30; severe RDI ≥30 [25].
2.3.2. ApneaLink. ApneaLink records patient respiratory
nasalpressureandbloodoxygensaturationduringsleep.The
nasal pressure is measured directly at the nostrils and is not
linear to the patient’s breathing ﬂow. In order to reestablish
this linearity, a mathematical formula is used for linearizing
the nasal pressure. The linearization ensures that even the
smallest changes in the patient’s breathing ﬂow are recorded
and evaluated validly [26]. The blood oxygen saturation and
pulse rate are measured using the ﬁnger pulse sensor and
the pulse oximeter (XPod, Nonin). The XPod module has
motion-tolerant software that minimizes the likelihood of
motion artifact being misinterpreted as good pulse quality.
The ApneaLink device operates on battery power, has a
sampling rate of 100Hz (airﬂow), 1Hz (oxygen saturation)
and a 20-bit signal processor. The internal memory storage
is 15MB, which allows for approximately 10 hours of
data collection. During the night of laboratory evaluation,
subjects also wear an ApneaLink device. The nasal cannula
used by the patients during the study is attached to a “T”
connector leading to a pressure transducer, allowing for the
simultaneous recording of the ﬂow signal by the ApneaLink
device and the PSG system.
ApneaLink Analysis. Using the ApneaLink software (version
9.00) installed in a PC, one blind observer (CAN) who was
independent from the results of the PSG performed the
automatic analysis ﬁrst, and then, he did the full manual
correction.
(i) Automatic Scoring: the ApneaLink default setting for
apneawasused.Anapneawasdeﬁnedasadecreasein
airﬂow by 80% from baseline for at least 10 seconds.
The ApneaLink default maximum apnea duration
was set at 80 seconds. A hypopnea was deﬁned as
ad e c r e a s ei na i r ﬂ o w≥30% from baseline for at
least 10 seconds plus oxygen desaturation ≥3%. The
ApneaLink default maximum hypopnea duration
was set at 100 seconds. The apnea/hypopnea index
was calculated as the number of apneas/hypopneas
per hour of automatic evaluation period (AHI-a).
(ii) Manual Scoring: once the ApneaLink program had
carried out the automatic analysis, the results were
r e v i s e di n3o r5m i ne p o c h sa n d ,w h e na p p r o p r i a t e ,
manually corrected by a physician trained (CAN)
in the reading of polysomnography. If required, the
operator could edit or delete events or insert new
ones. Likewise, it was possible to include or exclude
sectors of the recording for their analysis. Apnea
was deﬁned as the absence of airﬂow lasting ≥10s
from baseline for at least 10 seconds. Hypopnea
was considered when a reduction of airﬂow ≥10s
from baseline plus oxygen desaturation ≥3% or
evidence of autonomic arousal was identiﬁed at the
end of hypopneas or when only a reduction of
airﬂow ≥50% was observed. We used an increase
in the pulse rate of at least ﬁve beats per minute
as criterion for autonomic arousal [27, 28]. The
manual apnea/hypopnea (AHI-m) was calculated
as the number of apneas/hypopneas per hour of
evaluation period. The positive ApneaLink criteria
used in this study were an AHI-m ≥5.
2.4. Statistical Analysis. To assess if the study variables
had a normal distribution a frequency histogram and the
Kolmogorov-Smirnov test were performed. Thus, when the
distribution was normal, the mean and standard deviation
was reported. Instead, the median and the percentiles
25–75% were used if the distribution was not normal.
The degree of association among the manual ApneaLink
apnea/hypopnea index variables (AHI-m) and the res-
piratory disturbance (RDI) from polysomnography was
evaluated by the Pearson correlation coeﬃcient (r). The
nature and extent of the disagreement between the RDI
and the AHI-m were assessed by means of a Bland and
Altman plot. Accuracy of observer B on the indication of
CPAP was assessed by the receiver operating characteristics
(ROC) curve. Sensitivity, speciﬁcity as well as positive
and negative likelihood ratio (LR+, LR−)w e r ec a l c u l a t e d .
The interobserver agreement for the indication of CPAP
and manual scoring of ApneaLink was assessed by kappa
statistics.Thestatisticanalysiswasmadewithacommercially
available software programme (MedCalc Software, Version
11.3, Mariakerke, Belgium.
3. Results
Out of the 40 patients who were invited into the study, 39
gave informed consent and one patient was ruled out due
to an ApneaLink signal with frequent artifacts by ﬁnger clip
probe disconnections. Thus, 38 subjects provided acceptable
data for the ﬁnal analysis. The patient characteristics are
shown in Table 2. Men represented 68.5% of the study
sample. The prevalence of OSA in the sample study was4 Sleep Disorders
Table 2: Patient characteristics.
Patient number 38
Age (years) 47.5 ± 15.2
Men 26 (68.5)
BMI (body mass index—kg/m2) 31.4 ± 7.4
Prevalence of OSA (%)
RDI ≥ 5 32 (84.2)
Severity of OSA (%)
RDI ≥5–<15 9 (23.7)
RDI ≥15–<30 10 (26.3)
RDI ≥ 30 13 (34.2)
PSG
TRT (total recording time: min.) 362.9 ± 22.7
TST (total sleep time: min.) 317.2 ± 38.4
TWT (total wakefulness time: min.) 47.6 ± 36.5
SE (sleep eﬃciency) 0.87 ± 0.1
TNREM (min.) 283.2 ± 43
TREM (min.) 34 ± 29.1
RDI (respiratory disturbance index) 28.7 ± 7.3
Comorbidities
Hypertension 10 (26)
Coronary heart disease 3 (8)
Cerebrovascular ischemia 1 (3)
Arrhythmia 6 (16)
Asthma 1 (3)
Allergic rhinitis 11 (29)
Data are presented as mean ± SD, or n (%). OSA: obstructive sleep apnea.
TNREM: total stages 1 + 2 + 3 + 4; TREM: total amount of REM sleep.
84.2%. 23.7% had mild OSA and 60.5% of subjects had
moderate to severe sleep apnea (P<0.01).
There was a strong correlation between the AHI-m of
ApneaLink and the RDI from polysomnography (r = 0.944,
P<0.001) (Figure 1). The mean diﬀerence between the
manual scoring from ApneaLink (AHI-m) and the PSG
(RDI) was −1.7 ± 8.6 (Figure 2).
T h es e n s i t i v i t ya n ds p e c i ﬁ c i t yo fo b s e r v e rBt op r e s c r i b e
CPAP were 90.6%, and 100% respectively (see Table 3).
The false negative cases (FN) were three patients with
mild to moderate OSA (RDI: 7.3–21) who showed a total
sleep time and sleep eﬃciency lower than the true positive
(TP) patients. In addition, the FN had a higher proportion
of RERAs than the TP cases (see Table 4). The interrater
agreementforthe prescription of CPAPwasgood (k = 0.75).
Similarly, the agreement between observers for the manual
analysis of ApneaLink in a subgroup of 15 patients selected
at random was very good (k = 0.81).
4. Discussion
These data suggest that an experienced physician using
clinical parameters and the results of a device that measures
airﬂow by nasal pressure and oximetry (ApneaLink) might
prescribe a CPAP trial with reasonable accuracy in subjects
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Figure 1: Scatter diagram and regression line between the manual
AHI from Apnealink (AHI-m) and the respiratory disturbance
index of the polysomnography (RDI).
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Figure 2: Bland-Altman plot of manual ApneaLink apnea/hypop-
nea index (AHI-m) and the respiratory disturbance index (RDI)
from PSG.
with suspected OSA who had indication of initiating treat-
ment with CPAP by medical history and polysomnography.
This theoretical model to prescribe a CPAP trial had a
sensitivity of 90% and a speciﬁcity of 100%. Furthermore,
we observed a good agreement between observers for
prescribing a CPAP proof (k = 0.75). The main drawback of
this approach could be that 10% of patients with suspected
OSA, who could have beneﬁted with CPAP therapy, were
excluded from the treatment because they did not meet the
ApneaLinkorclinicalcriteriatoinitiateaCPAPtrial.Inthese
false negative cases, it would have been necessary to indicate
apolysomnographywiththeconsequentincreaseofthecosts
and delay in the diagnosis and treatment. On the other
hand, no patient initiated a trial of CPAP unnecessarily since
the speciﬁcity of this approach was of 100%. These results
are consistent with previous studies. Mulgrew et al. [29]
showedthatintheinitialmanagementofpatientswithahighSleep Disorders 5
Table 3:Sensitivity,speciﬁcity,positiveandnegativelikelihoodratio,andpredictivevalueofApneaLinkplusclinicaldatafortheprescription
of CPAP.
AUC-ROC (SE) Sensitivity (CI 95%) Speciﬁcity (CI 95%) +LR −LR +PV (CI 95%) −PV (CI 95%)
0.953 (0.026) 90.6 (75–98) 100 (54.1−100) 0.094 100 (87.7−100) 67 (30−92.5)
AUC-ROC:areaundertheROCcurve;SE:standarderror;+and −LR:positiveandnegativelikelihoodratio;+and−PV:positiveandnegativepredictivevalue.
CI 95%: conﬁdence interval 95%.
Table 4: Characteristics of false negative patients.
False negative True positive P
Number 3 29
Total sleep time 253.4 ± 11.8 329.2 ± 29 0.0003
Sleep eﬃciency 0.70 ± 0.06 0.90 ± 0.08 0.013
RDI 15.3 ± 7.1 35.7 ± 25.7 0.009
RERAs index 4.5 ± 4.2 0.98 ± 2 0.012
∗Values are expressed as mean ± SD. RERAs index: respiratory-eﬀort-
related arousals index.
probability of obstructive sleep apnea, polysomnography did
not confer any advantage over the ambulatory approach
based on oximetry and auto-CPAP in terms of diagnosis,
CPAP titration, and clinical outcomes. A recent simulation
study showed that two experts using a comprehensive sleep
history without a sleep study could have reliably initiated
CPAP in 52% of the patients with suspected OSA; this
results in signiﬁcant cost reduction [30]. Four prospective
randomized studies that used respiratory polygraphy [31,
32]o rl e v e l4s l e e pd e v i c e s[ 33, 34] have shown that the
clinical course of patients with OSA diagnosed and treated at
home with CPAP was similar to the group of patients who
underwent polysomnography with CPAP titration in the
sleep laboratory. Finally, we observed that the combination
of clinical data and oximetry had a high accuracy for
prescribing CPAP in patients with suspected OSA compared
withpolysomnography[35].Basedonourresults,inpatients
with high clinical pretest for OSA, we currently diagnose and
prescribe CPAP according to the results of the ApneaLink
conducted at home-plus-clinical parameters.
Our study has some limitations. A study to support a
treatment decision requires a greater number of patients.
This is a theoretical analysis of the usefulness of ApneaLink
andtheclinichistorytodiagnoseandindicateaCPAPtrialin
patients with OSA. In order to evaluate the accuracy of this
strategy in real life, it is necessary to conduct a randomized
study to draw conclusions that are more valid. As a new
approach for clinical decision making, it is necessary to look
at its inﬂuence on long-term outcomes like compliance of
CPAP and possible eﬀecton cardiovascular comorbidities. In
addition, the use of these diagnostic tools for the indication
of CPAP requires expertise in the diagnosis of sleep disorders
and training in the analysis of the ApneaLink.
In conclusion, this study has shown the use of an
approach based on ApneaLink, and clinical data has made it
possible to indicate CPAP reliably in most patients with high
clinical pretest for OSA. This approach could be used in sit-
uations where access to sleep studies is not possible, with the
consequent reduction of costs and rapid initiation of treat-
ment with CPAP, especially in the most severe forms of OSA.
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